tradingkey.logo

Aflac Q4 revenue beats analyst expectations on Japan growth

ReutersFeb 4, 2026 9:14 PM


Overview

  • Supplemental health insurer's Q4 revenue beats analyst expectations

  • Adjusted EPS for Q4 missed analyst estimates

  • Company announced a 5.2% increase in first quarter dividend


Outlook

  • Company plans to promote new products in Japan in 2026


Result Drivers

  • JAPAN SALES GROWTH - Aflac Japan's sales increased 15.7% in Q4, driven by strong demand for the new cancer insurance product, Miraito

  • U.S. PREMIUM INCREASE - Aflac U.S. net earned premiums rose 4.0% in Q4, reflecting improved sales and strong persistency

  • INVESTMENT INCOME DECLINE - Adjusted net investment income fell due to lower floating rate income and variable net investment income


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Revenue

Beat

$4.90 bln

$4.31 bln (5 Analysts)

Q4 Adjusted EPS

Miss

$1.57

$1.69 (13 Analysts)

Q4 EPS

$2.64

Q4 Adjusted Net Income

Miss

$818 mln

$887.88 mln (8 Analysts)

Q4 Net Income

$1.40 bln


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 8 "hold" and 3 "sell" or "strong sell"

  • The average consensus recommendation for the life & health insurance peer group is "buy."

  • Wall Street's median 12-month price target for Aflac Inc is $111.00, about 0.9% below its February 3 closing price of $112.04

  • The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 15 three months ago

Press Release: ID:nPn4YqXx9a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI